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Available online 12 December 2016Background:Acute andmedium-term intervention studies suggest that non-nutritive sweeteners (NNS) are ben-
eficial forweight loss, however there is limitedhumandata on the long-term effects of consumingNNS onweight
loss, maintenance, and appetite. Further research is therefore required to elucidate the prolonged impact of NNS
consumption on these outcome measures.
Methods/design:A randomized parallel groups designwill be used to assesswhether regular NNS beverage intake
is equivalent to a water control in promoting weight loss over 12-weeks (weekly weight loss sessions; Phase I),
then supportingweightmaintenance over 40-weeks (monthly sessions; Phase II) and subsequently independent
weight maintenance over 52-weeks (Phase III) in 432 participants. A subset of these participants (n= 116) will
complete laboratory-based appetite probe days (15 sessions; 3 sessions each at baseline, at the start of phase I
and the end of each phase). A separate subset (n= 50) will complete body composition scans (DXA) at baseline
and at the end of eachphase. All participantswill regularly beweighedandwill complete questionnaires and cog-
nitive tasks to assess changes in body weight and appetitive behaviours. Measures of physical activity and bio-
chemical markers will also be taken.
Discussion: The trial will assess the efficacy of NNS beverages compared towater during a behaviouralweight loss
and maintenance programme. We aim to understand whether the impact of NNS on weight, dietary adherence
and well-being are beneficial or transient and effects on prolonged successful weight loss and weight mainte-
nance through sustained changes in appetite and eating behaviour.
Trial registration: Clinical Trials: NCT02591134; registered: 23.10.2015
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Sugar-sweetened beverages (SSB)1. Introduction
The global rise in the prevalence of obesity is a major public health
concern [1] attributed to an ‘obesogenic environment’, characterised
by increases in low-cost, energy-dense foods and drinks, amongst
other lifestyle factors. Increased consumption of sugar-sweetened bev-
erages (SSBs) has been related to this rise in obesity prevalence [2,3,
4], possibly due to the poor satiating value of these beverages [5,6],
with individuals not responding to additional calories physiologically
[7] or cognitively [8,9]
Non-nutritive sweeteners (NNS) enable the consumption of sweet
tasting, yet low energy, foods and beverages. Low energy foods andne Building, Institute of Health,
of Liverpool, Liverpool B69 7ZA,
r Inc. All rights reserved.beverages could help reduce energy intake due to an absence of energy
compensation [10‐12] driven by changes in appetite regulation and gut
hormone release compared to SSB [12]. Consumption of these products
has been associated with reductions in body weight andweight-related
disease risk [13]. Recently, Peters et al., [14,15] provided participants
with either NNS beverages or water as part of a 12-week behavioural
weight loss programme to understand the effects of NNS during active
weight loss [14], followed by a weight maintenance period [15]. In the
longest study to date, the NNS group lost significantly more weight
and reported greater reductions in hunger after 12 weeks. This group
was also better able to maintain weight loss over the subsequent
40 weeks compared to control. These data indicate potential benefits
of including NNS products to help reduce and maintain reduced body
weight, although no mechanisms for these effects were examined. In-
deed, recent reviews of randomized controlled clinical trials (RCTs)
show associations between substituting SSBs for NNS and lowerweight,
fatmass, waist circumference and bodymass index (BMI) in both adults
and children [16]; long-term lower energy intake and weight loss
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tion between NNS and increased energy intake or weight [18]
Despite promising findings, concerns remain about the potential
negative impact of NNS beverages on appetite andweightmanagement.
Some argue that chronic NNS exposure may undermine energy regula-
tion by impeding the learned association between sweetness and ener-
gy [19,20]. Rodent studies suggest that NNS alter blood glucose levels
via altered post-prandial glucagon-like peptide 1 (GLP-1) secretion,
weakening the impact of sugars on the satiety hormone response [21],
whilst clinical studies of insulin sensitivity and GLP-1 release yield
mixed results [22,23,24,25]. Some epidemiological evidence suggest
an association between the use of NNS and obesity [26,13,27], though
findings may be explained by reverse causation [18,27].
The mechanisms by which NNS may affect energy balance and
weight maintenance during a long-term intervention still need to be
elucidated, including the influence on energy intake, compensation, ap-
petite control, and food choice which has not been quantified thus far.
The present research will examine (i) the effect of NNS beverages on
weight loss and long-termweightmaintenance and (ii) the behavioural
and biological mechanisms through which these effects arise as com-
pared to water.
2. Methods and materials
2.1. Outcome measures
2.1.1. Primary outcome measure
The primary outcome measure will be weight change (kg) from
baseline to post-weight loss phase (WLP) and weight maintenance
phase (WMP; end of year one).
2.1.2. Secondary outcome measures
2.1.2.1. Physiological. i) Anthropometric (waist and hip circumference)
and body composition (percentage fat mass
and total fat mass, upper body and lower body
fat and fat-free mass measurements using
DXA scanning in Subset 2).
ii) Biochemical changes in markers of glycaemic control (fasting insu-
lin, fasting glucose andHbA1c), fasting lipid profiles (total cholester-
ol, triglycerides, high density lipoprotein (HDL), low density
lipoprotein (LDL) and liver function tests (ALT, AST and GGT)).
2.1.2.2. Psychological. i) Measurements of appetite expression.
Changes in food preferences, cravings and eat-
ing behaviours (through 24-hour recall food
diaries, sweet food frequency questionnaires
(sFFQ) and associated craving questionnaires)
as well as changes in mood and mental well-
beingwill also be examined in the study popu-
lation as awhole. Appetite expression (hunger,
satiety, liking and wanting) and calorie intake
(food choice, macronutrient intake and energy
compensation) will be assessed in a subset
containing equal numbers of NNS beverage
and water consumers (Subset 1). These
between-group (and appropriate within-
group) comparisons will determine whether
the effects of NNS or water on subjective rat-
ings of appetite andmood are beneficial to suc-
cessful weight management (over the weight
loss and weight maintenance phases). Exami-
nation of food choice, changes in attitudes to
NNS or water, food preference, cravings andmacronutrient intake will investigate potential
detrimental or beneficial in preference for
sweetness.
ii) Experience and ease of weight loss in WLP and assisted WMP.
To determine the behavioural mechanisms of action when using
NNS or water during weight loss and weight loss maintenance in
those who regularly consume NNS and/or water beverages, the ex-
perience of and perceived ease of weight management will be
assessed by the inclusion of psychological cognitive tests and
questionnaires.
2.2. Trial design
The study will use a parallel randomized design with two arms: an
NNS beverage arm (active) or a water beverage arm (control). The
trial will enroll 432 participants. All participants will undergo an initial
12-week weight loss phase (WLP; Phase I) - in which participants will
attend weekly behavioural weight loss group sessions and incorporate
either NNS or water as their treatment group beverages into their diet
throughout the trial. Subsequently, participants will undergo a 40-
week assisted weight maintenance phase (WMP; Phase II) and attend
monthly group sessions (whilst continuing to consume NNS or water).
A third phase will consist of a further 12-month non-assisted WMP
(Phase III) inwhich participantswill not receive any further behavioural
and nutritional advice, but continue to consume NNS beverages or
water and complete monthly retrospective appetite and mood ratings
(Fig. 1). Two subgroups will additionally complete appetite probe days
(Subset 1; 15 sessions in total; n=116) or undergoDXA scanning (Sub-
set 2; 4 sessions in total; n = 50).
2.3. Participants
2.3.1. Inclusion criteria
The following inclusion criteria must be met: healthy overweight
and obese adult males and females (BMI: 27–35 kg/m2; age range:
18–65 y) who are either regular consumers (N3 drinks per week but b
2 l per day) of chilled NNS or are NNS beverage naïve (assessed as no
NNS or up to 25% NNS beverage choices made over the last five years).
Participants must accept randomization to either a water or NNS bever-
age condition and must be willing to abstain from consuming NNS bev-
erages (if randomized to the water condition) or willing to consume
NNS beverages (if randomized to NNS group) for the duration of the
trial. They must not be planning on moving from the Merseyside area
for the duration of their participation in the trial and they must provide
voluntary written informed consent.
2.3.2. Exclusion criteria
Exclusion criteria include: expressing a significant dislike of NNS
beverages (less than moderately likeable on a 7-point Likert scale);
first year University students (to avoid the ‘freshman 15’ phenomenon
of weight gain within the first year of attending University and thus in-
creasing variance in the sample; [29,30]); any significant health prob-
lems (including a history of cardiovascular diseases); any gastro-
intestinal problems; type 1 or type 2 diabetesmellitus; taking anymed-
ication or supplements known to influence appetite or weight within
the past month and/or during the study; statedmajor psychiatric disor-
der (made clear by medicines specified); currently suffering from de-
pression (made clear by medicines specified); currently being treated
for a psychological condition; pregnancy, planning to become pregnant,
breastfeeding or b6 months post-partum; history of anaphylaxis to
food; known food allergies or food intolerance; dislike of N25% of the
study foods offered on the appetite probe day (Subset 1 only); non-
breakfast eaters; smoking or having ceased smoking in the last six
months; currently dieting, having ceased a diet in b4 weeks, or having
Fig. 1. Study flow diagram. NNS = Non-nutritive sweetened.
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ular intense exercise (N2 h per week); having significantly changed
their physical activity patterns in the past 4 weeks or intending to
change them during the study (other than to adhere to advice given in
the behavioural intervention); inability to adhere to a defined exercise
programme such as inability to increase physical activity; receiving sys-
temic or local treatment likely to interfere with evaluation of the study
parameters;working in appetite or feeding-related disciplines; being on
specific food avoidance diets; having had bariatric surgery; having ab-
normal eating behaviour (restrained eaters measured by the Dutch Eat-
ing Behaviour Questionnaire Restraint Scale [DEBQ-R] with a cut-off
point of N4 [31]); and binge eaters measured by the Binge Eating Scale
[BES] with a cut-off point of 27 or over [32]). Only one individual per
household will be eligible for inclusion.2.3.3. Recruitment
Participants will be recruited from the Merseyside area of En-
gland. Volunteers who respond to the study advertisements (verbal
advertisements e.g. radio; text advertisements e.g. newspapers and
posters; and social media e.g. Facebook and Twitter) will be given
full information on the study and the process of informed consent
will be undertaken. All measurements will be conducted by trainedstaff in the University of Liverpool. Recruitment will commence in
July 2016.
2.4. Randomization
Participants will be randomized to condition (NNS or water) after
their initial screening session. This will be stratified using block ran-
domization (random block sizes of 4 and 6) to ensure equal numbers
of participants are randomized to each arm (1:1) using a computer-
generated randomization sequence. Randomization strata will be
based on sex (male/female), age (19–34 y; 35–50 y; 51–65 y), BMI
(b30 kg/m2 and N30 kg/m2) and beverage consumption (NNS naïve
or regular NNS consumption). Participants from the same household
will not be accepted into the trial to account for likely data clustering.
Randomization will be carried out by an academic investigator who
is not involved in the implementation of the trial and will be con-
ducted using a database only seen by this academic investigator.
Once the participant has passed the screening stage, the academic in-
vestigator will be providedwith the strata required to allocate condi-
tion and the researcher will inform the participant upon their second
visit to the laboratory.
Randomization to each group will also be completed for the subsets
of participants taking part in the appetite probe day sessions (Subset
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trol participants in each subset.
2.5. Withdrawal
Participation in the study is voluntary, and participants may with-
draw from the studywithout providing a reason. If a participant chooses
to withdraw, every effort will be made to complete early termination
assessments if applicable. Any participant who has completed two
weeks or more of the WLP and decides to discontinue will be encour-
aged to undergo an early termination visit if willing. The participant
will be contacted on three occasions and if no response is made the par-
ticipant will be excluded from further measures.
2.6. Intervention
2.6.1. Beverage condition
NNS participants will be asked to consume at least two servings (2 ×
330 ml) of NNS beverage per day (still or carbonated) during the trial.
Control participants will be asked to consume at least two servings
(2 × 330 ml) of water per day (still or carbonated) and will be asked
to refrain from consumingNNS beverages. Tominimise participant bur-
den, beverages will be supplied using a home shopping delivery-style
service with participants selecting beverages from a pre-defined list to
be delivered to their home.
2.6.2. Adherence
Compliancewill be assessed using an online daily beverage log of all
drinks consumed (including detail of volume and energy content)
throughout the trial. Similarly, participants will be periodically asked
to return empty packaging of their elected drinks during the WLP,
assisted WMP and non-assisted WMP. 24-hour dietary recalls will be
completed at various stages throughout the trial and can be utilized as
an additional adherence measure.
2.6.3. Adverse events
Overall, no immediate risk is anticipated with the current study. In-
deed, a previous study has utilized a similar design with no negative
outcomes to participants [14,15]. Nevertheless, the monitoring of ad-
verse events will be carried out at monthly intervals throughout the
trial.
2.6.4. Use of NNS
The sweeteners in the NNS beverages provided have been approved
by the European Food Safety Authority (EFSA) and are safe at the doses
to be consumed. The tolerable daily intake (TDI) of aspartame, for ex-
ample, is 40mg/kg bodyweight per day [33]. For an overweight female
weighing 80 kg (height 168 cm; BMI 28.6 kg/m2) thiswould be 3200mg
on a daily basis. To put this into perspective, themost oneNNS beverage
portion (330ml) is likely to provide is 192mg of aspartame. For this in-
dividual 16.6 cans (or 5478 ml) NNS beverage would need to be con-
sumed each day – a quantity far exceeding that provided to
participants in this trial - to achieve the TDI.
2.7. Measurements and visits
2.7.1. Psychological measurements
A range of questionnaires and cognitive tests assessing secondary
outcomes of appetite, craving and mood will be completed at baseline
and at the end of each phase of the trial - the WLP (Phase I), assisted
WMP (Phase II) and at the end of the non-assisted WMP (Phase III).
For appetite, craving and eating behaviours (including food choice)
these include: the Three Factor Eating Questionnaire (TFEQ; [34]) mea-
suring eating behaviours; Power of Food Scale (PoF; [35]) measuring dif-
ferences in hedonic hunger; Eating Self Efficacy andWeight Self Efficacy
[36] measuring self-perceived ability to control eating and weight;Attitudes towards NNS Beverages and Watermeasuring participant's be-
liefs and attitudes about these beverages; Craving for Sweet Foods Ques-
tionnaire assessing desire for sweet foods; the 7-day (and 24-hour for
Subset 1) Control of Eating Questionnaire assessing specific food cravings;
mini-IPIP personality trait measure [37]; Self-reported Eating Rate [38];
Plate Clearing [39]; Retrospective Experience of Appetite (aVAS). Three
24-hour recalls will be completed at four points; before starting the
WLP, at the end of the WLP, at the end of the assisted WMP and at the
end of the trial. The sFFQ will also be used throughout the WLP and
the assisted WMP and at the end of the trial (end of non-assisted
WMP) as a means of assessing whether beverage condition influences
sweet food intake. Additional cognitive tasks will also be performed
and include the Leeds Forced Choice Test and the Leeds Food Preference
Questionnaire [40] assessing the desire for a range of sweet and savoury
high and low fat items. Expected satiation of beverages will be assessed
using a computerized task as developed by Martin et al. [9]. Visual ana-
logue scale (VAS) questionnaire will be used to assess expected liking,
actual liking and actual satiation of NNS beverages or water (see
Table 1 for a schematic representation of study visits).
For experience of the WLP and WMP: Experience of Programme
(eVAS), Entering Treatment Self-Regulation Questionnaire (ETSRQ), Con-
tinuing Treatment Self-Regulation Questionnaire (CTSRQ) and Diet Self-
Regulation Questionnaire (DSRQ) measuring motivation to participate
in treatment and how much of this is controlled (perceived pressure)
or autonomous (personal reasons).
For mood and well-being: Profile of Mood States (POMS; [41])
assessing mood disturbances; Perceived Weight Status [42]; Everyday
Weight Discrimination Scale [43]; Exercise Avoidance Scale [42]; Self-
Esteem Scale [45]; Short Warwick-Edinburgh Mental Well-being Scale
[46]; Satisfaction with Life Scale [47],and the Retrospective Experience of
Mood (mVAS).
2.7.2. Exercise measurements
Activity monitors (Fitbit) will be supplied to all participants andwill
be worn every day for one week during relevant periods. Specifically,
they will be provided at baseline and at the end of each phase of the
trial (WLP, assistedWMP and non-assistedWMP). The wristbands con-
sist of a simple band strapped around the wrist which displays and
tracks total step count, total minutes of physical activity (separated
into light, moderate and vigorous), total minutes sedentary, and total
calories burned. Display screens will be covered to ensure participants
cannot track their progress. Participants will be provided with instruc-
tions of use and will be asked to wear the device continuously other
than to recharge the device, when in prolonged contact with water (N
20 min), or when sleeping.
2.7.3. Biochemical measurements
Fasting blood samples will be collected from all willing participants
(participants will not be excluded on the basis of not consenting to sup-
ply samples) at baseline and at the end of each phase - WLP, assisted
WMP and non-assisted WMP (4 visits in total). They will be analysed
for HbA1c, fasting glucose, fasting insulin, lipid profiles (total cholester-
ol, triglycerides, high density lipoprotein (HDL), low density lipoprotein
(LDL)) and liver function tests (ALT, AST, GGT). The blood samples will
be drawn from the antecubital vein with the participant in a fasting
state (10 h fast with only water consumption permitted) and after at
least 5 min rest by trained research staff. Samples will be sent daily to
the Royal Liverpool University Hospital where analysis will take place
in accredited biochemical laboratories.
2.7.4. Screening visit
The study protocol will be fully explained to participants (including
information about Subsets 1 and 2). Clinical measures will be assessed
after consent forms have been signed. Participants will then complete
a range of questionnaires assessing abnormal eating behaviour, their
medical history, liking for and use of NNS beverages and possible food
Table 1
Schematic presentation of study visits. DXA= Dual-energy-X-ray Absorptiometry; ET = early termination; FFQ= Food Frequency Questionnaire; N-WMP=Non-AssistedWeight Maintenance Phase, no = number; Sub = Subset, Q= Question-
naire, ET – Early Termination.
Screening Weight loss phase Active weight maintenance phase N-WMP
Week no −2 −1 −1 0 0 1 1 2 2 2 3 4 5 6 7 8 9 10 11 11 11 12 12 12 14 19 24 28 32 36 40 44 48 50 50 51 52 52 53–103 104
Visit no 1 1a 1b 1c 2 3 3a 3b 3c 4 5 6 7 8 9 10 11 12 13 13a 13b 13c 14 15 16 17 18 19 20 21 22 23 24 24a 24b 24c 25 26/ET 27–38 39
Informed consent x
Inclusion/exclusion criteria x
Medical history x
Q: Screening x
Concomitant meds x
Adverse events x x X x x x x x x x
Group meeting x x x x x x x x x x X x x x x x x x x x x x
DXA Scan (Sub 2) x x x x
Bloods x x x x
Randomization x
Body weight x x x x x x x x x x X x x x x x x x x x x x x x x
Height x
Blood pressure x x x x
Waist & Hip circumference x x x x x x x x x x x x x x x
Appetite probe (Sub1) x x x x x x x x x x x x x
Q: Probe day Qs (Sub1) x x x x x x x x x x x x x
3-d Diet Diary x x x x
Sweet FFQ x x x
Beverage & Exercise Log x x x x x x x x x X x x x x x x x x x x x x x x x
Activity armband x x x
Product delivery x x x x x x x x x x x x x x x x x
Product drop off x x x x x x x x X x x x x x x x x x x x x x
Q: Programme experience x x x x x x x x X x x x x x x x x x x x x x x x
Q: Eating behaviour x x x x x
Q: Attitude beverages x x x x
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85U. Masic et al. / Contemporary Clinical Trials 53 (2017) 80–88allergies. Upon successfully passing the screening visit, subsequent
study visits will be arranged.
2.7.5. Individual visits
Participants will complete the full range of psychological measure-
ments at individual visits before onset of the WLP, before the assisted
WMP, at the end of assisted WMP and at the end of the non-assisted
WMP. Participants will be fasted (10 h fast), will provide blood samples
(if they have consented to this aspect of the trial) and will then be pro-
vided with a breakfast before completing the questionnaire and cogni-
tive measures.
2.7.6. Weight loss phase (WLP)
The 12-week weight loss phase (WLP) will be based on a dietitian-
designed nutritional knowledge and group work programme incorpo-
rating a social cognition-based approach (The Colorado Weigh) used
by Peters et al., [14,15]. This employs a groupbased approach (6–20 par-
ticipants)with frequentmeetings (one perweek) for a one hour session
with a nutritionist-trained researcher who will supervise each session
and who will provide materials for participants to complete before
their next session. Weight will be measured privately at the start of
group sessions with each participant in a separate area. Anthropomet-
rics (waist and hip measures) will be taken every four weeks through-
out the WLP and blood pressure readings will be taken at baseline, at
the end of the WLP, at the end of the aWLP and at the end of the trial.
Participants will begin to log their daily beverage intake (which will
continue over entire trial duration) online as well as their exercise
(only completed during the WLP and assisted WMP).
2.7.7. Assisted weight maintenance phase (WMP)
The assisted WMP will be conducted in the same groups of partici-
pants (6–20) utilizing the Colorado Weigh programme. Sessions will
be conducted once per month over this 40-week period. Body weight
and anthropometrics (waist and hip measures) will be measured pri-
vately at the start of each session and an additional blood pressure read-
ing will be taken at the last session.
2.7.8. 12-Month non-assisted maintenance phase and final visit
After the final assisted WMP visit, participants will continue to re-
ceive either NNS or water beverages for 12 months during the non-
assisted WM period. They will be asked to complete the Retrospective
Experience of Appetite questionnaire (aVAS), Experience of the Pro-
gramme (eVAS), and Retrospective Mood Questionnaire (mVAS) at
monthly intervals. They will also continue to complete daily beverage
and exercise logs online over the duration of the 12-month period.
2.7.9. Appetite probe day sessions (Subset 1)
A voluntary subset of randomly selected participants (n = 116; 58
NNS and 58 water) will be invited to additionally participate in the ap-
petite probe day sessions to assess changes in appetite response to en-
ergetic (SSB) and non-energetic (water and NNS) beverages. These
probe days will be measured at baseline, at the start and end of the
WLP, at the end of the assisted WMP and at the end of the non-
assisted WMP (15 visits in total). Although the start of WLP probe ses-
sions will be recently after the baseline sessions, the mind set of partic-
ipants is anticipated to be different due to the structured WLP sessions
being received, thus capturing changes in food choice and energy intake
at this early stage. At each time point, one probe day will examine the
response to a SSB and on the second and third the response to NNS
and water, respectively (the order of all three drinks will be
counterbalanced across participants and probe days). On these days,
participants will consume the SSB, NNS beverage or water and will
not be asked to consume their two portions of NNS or water beverage.
Participants will be provided with a fixed load breakfast (providing
25% energy from estimated RMR), themidday beverage preload follow-
ed 1 h later by an ad libitum lunch and a further 4 h later by an adlibitum dinner which they will self-serve. Participants will then be pro-
vided with a snack box to consume at will for the remainder of the eve-
ning after dinner. They will also complete appetite and sensory VAS
ratings throughout the day (including specific beverage appetite VAS
questionnaires) and retrospective appetite and craving questionnaires
at the end of the day. Energy compensation will be tracked at the ad
libitum test lunch, evening meal and snack box. Participants will not
be provided with any information about the drinks during the probe
days; however the sensory characteristics of the beverages may be
evident.
2.7.10. DXA scan sessions (Subset 2)
In addition to trial participation, Subset 2 (n = 50; 25 NNS and 25
water) will be asked to provide a full body DXA scan after an overnight
fast at baseline, at the end of the WLP, assisted WMP and at the end of
the non-assistedWMP(4 visits in total). TheDXA scanwill be used to as-
sess changes in body composition during the trial. Body composition
will be determined to quantify total and regional (trunk, limb, android
and gynoid) fat mass and fat-free mass.
2.7.11. Statistical analysis
2.7.11.1. Sample size calculation. The power calculation is based on a sim-
ilar trial previously conducted [14] using bounds of equivalence which
were set to ±1.5 kg for weight loss. Although Peters et al. [14] powered
for a ±1.7 kg weight loss it is notable that in the EU smaller differences
inweight loss between groupsmay be considered significant. For exam-
ple, significant and clinically meaningful effects of 1.5 kg placebo
subtracted weight loss have been sufficient to produce a successful
EFSA health claim for weight management [48]. The current trial is
powered for a primary outcome of weight loss of 90% power with a
two-sided α equal to 0.05 for bounds of equivalence set to ±1.5 kg
for weight loss. The standard deviation for group differences in weight
loss (±3.58 kg) was derived from Peters et al., [14]. Factoring in a 27%
attrition rate (average attrition found by Peters et al., [14]) it is estimat-
ed that 158 participants will be required in each condition (n = 316).
A separate power calculation was carried out for Subset 1 (probe
day) participants based on one between-subjects condition and five as-
sessment periods and calculated to 90% power and a small to moderate
effect size (f=0.20; G*Power software). Theαwas set to 0.01 to repre-
sent a partial correction [47] for comparing multiple appetite measures
and moderate correlations between the measures were also assumed
(r = 0.3). This power analysis indicated 58 participants were required
in each group (n = 116) to power for identification of a significant
within-between interaction whilst taking into account a 27% attrition
rate.
2.7.11.2. Primary outcome measures analysis. Changes in mean body
weight from baseline to the end of the assisted WMP (end of year
one) will be compared using a 2 × 2 mixed ANCOVA-type model with
a between-subjects group factor and within-subjects factor of time
and also including baselineweight, age, sex, NNS naiveté and additional
covariates as appropriate.
2.7.11.3. Secondary analyses. Changes in anthropometrics and body com-
position (DXA) will be assessed at the same time points as weight
change using an ANCOVA-typemixedmodel with a group-time interac-
tion and also including baseline weight, age, sex, NNS naiveté and addi-
tional covariates as appropriate. All questionnaire, cognitive task,
biochemical bloods analysis, food diary and exercise data will also be
assessed in this way. Group effects as well as other predictive relation-
ships will be explored using multiple linear regression and ANCOVA-
typemodels, including relevant covariates as appropriate. Factor analy-
sis may be employed to construct latent variables of overarching con-
structs (for instance individual measures that tap into a single
underlying construct, such as craving-type measures will be found)
86 U. Masic et al. / Contemporary Clinical Trials 53 (2017) 80–88reducing the number of tests run whilst simultaneously capturing as
much variance as possible in underlying constructs. This part of the
analysis is data driven and therefore cannot be influenced by experi-
menter bias. It is notable that condensingmeasures, through their com-
bination, also limits the issues encountered when applying multiple
comparisons. Multiplicity adjustment of p-values will be carried out
for pairwise comparisons of groups in the analyses of the primary and
secondary outcomes.
In order to investigate the impact ofmissing data on the primary and
secondary analyses, three analysis approaches will be taken. Firstly, a
complete-case analysis (CCA) will be carried out. In addition to this,
we will also conduct Intention-to-Treat (ITT) analysis which incorpo-
rates baseline carried forward (BCF); a last observation carried forward
(LOCF) analysis; and an analysis of estimated data conducted using a
multiple imputation (MI) analysis. In addition, available-case analyses
utilizing all available data will be applied for the exploratory analyses
as appropriate.
3. Discussion
The present trial aims to assess the effects of NNS beverages, as com-
pared to water, on short- and long-termweightmanagement (incorpo-
rating weight loss and long-term weight maintenance). It also
investigates the underpinning behaviouralmechanisms (appetite, ener-
gy intake, food choice,mood, attitudes, experiences and changes in pref-
erence) that mediate these effects.
Currently, the literature on NNS use in weight gain prevention and
weight loss is equivocal, with trial outcomes ranging from NNS use
supporting weight loss efforts and diet adherence [14,15,16,18,50,51]
through a lack of effect on weight gain [11,12,17,28]. Indications that
NNS contribute to obesity have been suggested in rodent studies [19,
20,21,22,52]. Thus, further studies are required to elucidate the role of
NNS in weight loss and also during long-term weight maintenance,
even if the results of some short and long-term interventions appear
promising [14,15].
The present intervention will be two years in length for each partic-
ipant investigating the effects of NNS beverages compared towater dur-
ing distinct periods of weight change. This includes three discrete
phases: Phase I - weight loss (12-week dedicated weight loss phase
with weekly dedicated dietitian-led group sessions), Phase II - assisted
weight maintenance (40-week phase with monthly dedicated
dietitian-led group sessions) and Phase III - non-assisted weight main-
tenance (12-month phase of NNS or water consumption). Assessments
of body weight will determine changes in overall weight loss or gain
and body compositionwill further explore differences in body fat distri-
bution. The analysis of fasting blood samples will provide a clearer in-
sight into the biological impact of NNS beverages, as compared to
water controls, on biomarkers of metabolic health, appetite and satiety.
The proposed research is novel not only due to its extended two year
duration but also due to the wealth of psychological measures examin-
ing the potential behavioural mechanisms of action underlying weight
change. In addition to assessment of body weight and anthropometrics,
examination of the experience of and perceived ease of weightmanage-
ment in the two groups during these periods will determine whether
NNSorwater consumption aid adherence to aweightmanagement pro-
gramme in those who either regularly consume NNS beverages or are
largely naïve to NNS beverages. Furthermore, a systematic comparison
of the effects of beverages (NNS, water and SSB) on appetite expression
(satiation, satiety, liking and wanting) and energy intake (food choice
and energy compensation) in a subset of the study population as well
as the examination of changes in food preferences, cravings and eating
behaviours (through food diaries and associated questionnaires) in
the full study population will determine whether the effects of NNS on
appetite are equivalent to water in aiding successful weight manage-
ment (over the weight loss and weightmaintenance phases). Examina-
tion of food choice, food preference, cravings and macronutrient intakewill specifically highlight potential detrimental or beneficial changes in
preference for sweetness as a result of NNS use.
This research will provide a comprehensive view of the role of NNS
beverages in our current environment and the behaviouralmechanisms
underlying observed effects, particularly the long-term effects of such
beverages on weight loss and weight maintenance. To our knowledge,
such a detailed assessment of the role of NNS beverages as compared
to water has not been conducted and would be an invaluable addition
to the existing literature.3.1. Research governance
3.1.1. Ethical approval
The University of Liverpool is the Sponsor of the trial (version 2
dated 16.12.2015). The trial was registered at Clinical Trials
(NCT02591134) on 23.10.15. Ethical approval was received from the
NRES Ethics Committee North West - Liverpool East on 19.05.2016
(Ethics Ref: 16/NW/0347).3.1.2. Study sponsor
The University of Liverpool is the study sponsor and all researchwill
be conducted within the University in accordance with the Research
Governance Framework. All responsibility regarding the recruitment,
running, management and financial arrangements will be through the
Institution. Potential risks identified will be reported and managed to
ensure research follows Good Clinical Practice (GCP) guidelines to the
extent that it is reasonably practicable in a non-medical trial to ensure
the highest quality research. Funding for the study is provided by the
American Beverage Association.3.1.3. Data handling and quality assurance
All research undertaken will comply with Good Research Practice
guidelines. This involves particular attention to confidentiality and com-
pliance with the Data Protection Act. Personal data will be stored se-
curely at the research site and will only be accessible to the research
team. All samples and data will be anonymized before analysis and
study data will be stored separately from any personal information
with separate anonymized codes. No publications will contain informa-
tion that will be able to identify individual participants. All information
provided throughout the study will be treated as confidential. Paper
copies of the data will be kept in locked cabinets and any computerized
data will be stored on password protected computers.
The University of Liverpool will be the custodian of the data and will
ensure compliance with the Data Protection Act. Data and all appropri-
ate documentation will be stored for a minimum of 15 years after the
completion of the study.3.2. Research dissemination
Data analysis will be conducted according to analysis plans and will
be completed within the funded time period for the analyses specified
in the current proposal. Results from the study will be summarized
and published in peer-reviewed scientific and open access journals
and/or presented at scientific conferences. As the funding body, the
American Beverage Association (ABA) understands that they will have
no influence on data collection, analysis or interpretation or writing of
the report. The ABA will however have the opportunity to review the
draft manuscript at least four weeks prior to submission and provide
input for consideration by the researchers. The principal investigator
will ultimately be responsible for publishing the findings. The publica-
tion may be delayed up to a maximum period of six months to protect
commercially sensitive information, if warranted.
87U. Masic et al. / Contemporary Clinical Trials 53 (2017) 80–883.3. Trial status
Ongoing. The study date deadline is July 2019 or once 432 partici-
pants have been recruited and have completed the study (including
the 12-month non-assisted WM period).
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